Your Biopharmaceutical Development and Manufacturing Partner

First vaccines targeting 'cruise ship virus' sail into clinical trials - September 2013

Nanotherapeutics, a company based in Alachua, Florida, is betting that a nasal norovirus vaccine will have greater efficacy. The vaccine, which Arntzen helped develop, consists of a dry powder that will be squirted into the nose with a burst of compressed air.

Full Article

Copyright 2017 NANOTHERAPEUTICS, INC.  All rights reserved.